Canada’s PlantForm has struck a deal with Brazil’s Bio-Manguinhos/Fiocruz to develop a biosimilar pembrolizumab rival to Merck’s Keytruda for the Brazilian market and potentially beyond.
Canada’s PlantForm has signed an agreement with Brazil’s Bio-Manguinhos immunobiological technology institute within the Oswaldo Cruz Foundation (Fiocruz) biologics research and development organization to develop a biosimilar of Merck’s Keytruda (pembrolizumab) for the Brazilian market.
The deal also involves the PlantPraxis joint venture formed in 2014 by PlantForm and Brazil’s PharmaPraxis to develop, manufacture and...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
